VC: Morphotek lands $40M VC round



Morphotek lands $40M VC round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Morphotek
Exton, PA

$40M
Fourth

Investor Growth Capital of New York

Morphotek's lead antibody, MORAb-003, specifically targets the folate receptor alpha, a cell surface receptor over-expressed on ovarian, breast, colorectal, lung and renal tumors.

MTM Laboratories
Germany

$27.5M
Third

HBM BioCapital

Much of that money will go to the development and commercialization of its diagnostic and screening devices for cervical cancer.

Achaogen
South San Francisco, CA

$26M
Second

Domain Associates

The company will use the money to advance its lead antibacterial program through clinical proof of concept, and to progress additional programs through preclinical development.

EnVivo Pharmaceuticals
Watertown, MA

$24M
Third

Fidelity Biosciences

EnVivo's first program to enter clinical development later this year is an alpha-7 nicotinic receptor agonist for cognition enhancement in Alzheimer's disease and schizophrenia.

Amyris Biotechnologies
Emeryville, CA

$20M
First

Khosla Ventures

Amyris is using synthetic biology techniques to develop rare chemicals for use in pharmaceuticals and energy.

Santhera Pharmaceuticals
Switzerland

$12.5M
Third

NGN Capital

Santhera has a Phase IIb trial underway for JP-1730/fipamezole with Juvantia for Dyskenesia in Parkinson's.

CoDa Therapeutics
San Diego, CA

$10M
First

Domain Associates

CoDa says it expects to add $5 million to $10 million more to that amount in the next 90 days. Much of that money will go to completing clinical trials.

AGI Dermatics
Freeport, NY

$5.5M
First

Trevi Health Ventures

AGI is developing skin cancer prevention therapies along with skin care products.

Prolacta Bioscience
Monrovia, CA

$5M
Second

Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, and the Gideon Hixon Fund

Prolacta specializes in the nutritional needs of underweight, premature, and critically ill babies.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.